Samodzielny Publiczny Zespol Opieki Zdrowotnej W Swidnicy
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Samodzielny Publiczny Zespol Opieki Zdrowotnej W Swidnicy includes studies in cardiovascular disease focused on patients after acute myocardial infarction. The main goal is to evaluate whether a new anti-inflammatory approach can help lower the risk of major heart-related events and improve long-term protection after a heart attack.
- Reduction of major adverse cardiovascular events in people with STEMI and NSTEMI
- Testing a therapy that targets inflammation linked to heart damage
- Improving prevention after acute coronary syndrome
These studies reflect a strong interest in better post-heart-attack care and in finding treatments that go beyond standard cardiovascular treatment.
Digestive System Diseases
The site also supports trials in digestive system diseases, especially gastric cancer and gastroesophageal junction adenocarcinoma. Research here is centered on testing new treatment combinations that may improve survival and disease control for patients with advanced cancers of the stomach and upper digestive tract.
- Studies in gastric adenocarcinoma and gastric cancer
- Research in gastroesophageal junction adenocarcinoma
- Evaluating whether new combinations can improve treatment effectiveness
At this hospital, the focus is on expanding options for patients with difficult-to-treat gastrointestinal cancers.
Neoplasms
On the oncology side, the Regionalny Szpital Specjalistyczny "Latawiec" w Świdnicy Oddział Onkologii Klinicznej is involved in trials for several cancers, including triple-negative breast cancer and upper gastrointestinal tumors. These studies are designed to assess whether newer targeted and immune-based treatments can improve outcomes compared with standard therapy.
- Research in locally recurrent or metastatic triple-negative breast cancer
- Testing new approaches that combine targeted therapy and immunotherapy
- Exploring better ways to manage advanced oncology cases
The site’s oncology department contributes to clinical research aimed at offering more effective treatment choices for patients with advanced neoplastic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Samodzielny Publiczny Zespol Opieki Zdrowotnej W Swidnicy
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK 009) | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Jan 2020 | Nov 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 2 | Unknown | 2020-01-17 | 2025-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.